


Financial Results of the 2nd Quarter for Fiscal Year Ending June 2024

February 14, 2024

(Securities code: 7747 Prime of Tokyo Stock Exchange,
Premier of Nagoya Stock Exchange)

A decorative graphic consisting of multiple overlapping, wavy lines in shades of gray, creating a sense of movement and depth across the lower half of the page.

FYE June 2024 Q2 YTD Main Points - 1

Revenue 54,341 Mil.Yen <Year-on-year +19.6%>

Increased both Medical and Device Division due to increased exchange rate fluctuation, the recovery and expansion of cases and strong demand, etc.

(Although there is concentration of orders in 1H for some distributor transactions, sales remained strong even after taking these factors consideration)

■ Medical Division ~Progressed favorably not only Cardiovascular but also Non-cardiovascular and OEM business~

- External environment : Expanded and increased in the number of cases due to disappearing the impact of Covid-19(YoY+3.4%)
Increased revenue due to the exchange rate fluctuation (Yen depreciation)
- In Cardiovascular field: Increased in all regions, centered on PCI GW and Penetration Catheter. Although there was a concentration of orders for transactions for distributors in Europe (Eastern Europe) and the Chinese market, sales remained strong in all regions even after considering the impact
- In Non-Cardiovascular field: Increased in all regions. Especially strong sales in China (all fields) , US (Peripheral vascular), etc.
- OEM business: Increased in new transaction mainly in US market

■ Device Division ~ Increased in Medical Components in overseas market mainly in US ~

- External environment : Increased in revenue due to the exchange rate fluctuation(Yen depreciation)
- In Medical Components business: Increased in Cardiovascular ultrasound catheter components for US companies
- In Industrial Components business: Decreased in leisure-related and construction-related transactions

□ Impact of increased revenue due to exchange rate fluctuation (Yen depreciation) +2,231 Mil. Yen

FYE June 2024 Q2 YTD Main Points - 2

Increased in operating income due to increased in revenue despite increasing SGA

- **Gross profit: 35,191 Mil.Yen < YoY +17.1% >**
 - Increased in gross profit due to increased in revenue
- **Operating income excluding goodwill amortization, etc.: 14,484 Mil. Yen < YoY +32.9% >**
 - Increased in revenue and expenses related to sales promotion activities in overseas market
 - Increased in R&D expenses (5,305 Mil.Yen) (YoY +541 Mil.Yen, R&D-to-Revenue ratio 9.8 %)
- **Operating income: 13,498 Mil.Yen <YoY +35.6% >**
 - Increased in goodwill amortization, etc. (985 Mil. Yen) (YoY +36 Mil. Yen)
- **Ordinary income: 13,471 Mil.Yen <YoY +40.0% >**
 - Decreased in foreign exchange loss (YoY -158 Mil.Yen)
- **Net Income attributable to parent company shareholders: 9,820 Mil.Yen <YoY +31.4% >**
 - Decreased in insurance proceeds on disaster at Cebu factory (YoY -305 Mil.Yen)

| Exchange rate (Unit : JPY) | US \$ | EURO | CNY | BAHT |
|-------------------------------|--------|--------|-------|------|
| FYE June 2024 Q2 YTD | 146.35 | 158.20 | 19.95 | 4.14 |
| FYE June 2023 Q2 YTD | 139.97 | 141.84 | 20.03 | 3.85 |

Highlights

| | FYE June 2023 Q2 YTD | | FYE June 2024 Q2 YTD | | | | | | |
|--|-------------------------|--------------|------------------------------------|----------------------|--------------|-----------------------|----------------|-------------------------------|----------------|
| | Amount (Mil.Yen) | Ratio (%) | Initial plan August 14, 2023 | Amount (Mil.Yen) | Ratio (%) | YoY | | Compared with Initial plan | |
| | | | | | | Changes (Mil.Yen) | Changes (%) | Changes (Mil.Yen) | Changes (%) |
| Revenue | 45,435 | 100.0 | 49,979 | 54,341 | 100.0 | +8,906 | +19.6 | +4,362 | +8.7 |
| Gross Profit | 30,040 | 66.1 | 33,099 | 35,191 | 64.8 | +5,151 | +17.1 | +2,092 | +6.3 |
| Operating Income excluding goodwill amortization, etc. | 10,901 | 24.0 | 11,654 | 14,484 | 26.7 | +3,583 | +32.9 | +2,829 | +24.3 |
| Operating Income | 9,951 | 21.9 | 10,720 | 13,498 | 24.8 | +3,547 | +35.6 | +2,778 | +25.9 |
| Ordinary Income | 9,621 | 21.2 | 10,671 | 13,471 | 24.8 | +3,849 | +40.0 | +2,799 | +26.2 |
| Net income attributable to parent company shareholders | 7,473 | 16.4 | 8,078 | 9,820 | 18.1 | +2,346 | +31.4 | +1,741 | +21.6 |
| EPS (yen) | 27.52 | — | 29.74 | 36.15 | — | +8.63 | +31.4 | +6.41 | +21.6 |
| EBITDA | 14,257 | 31.4 | 15,285 | 18,258 | 33.6 | +4,000 | +28.1 | +2,972 | +19.4 |

Revenue by Segment Year-on-year

| | FYE June 2023 Q2 YTD | | FYE June 2024 Q2 YTD | | | |
|--------------|-------------------------|--------------|-------------------------|--------------|----------------------|----------------|
| | Amount (Mil.Yen) | Ratio (%) | Amount (Mil.Yen) | Ratio (%) | Changes (Mil.Yen) | Changes (%) |
| Medical | 39,695 | 87.4 | 48,369 | 89.0 | +8,674 | +21.9 |
| Device | 5,740 | 12.6 | 5,972 | 11.0 | +231 | +4.0 |
| Total amount | 45,435 | 100.0 | 54,341 | 100.0 | +8,906 | +19.6 |




(Reference)

| | | | | | | |
|---------------|---------------|-------------|---------------|-------------|---------------|--------------|
| Medical Field | 43,145 | 95.0 | 52,227 | 96.1 | +9,081 | +21.0 |
| Device Field | 2,290 | 5.0 | 2,114 | 3.9 | -175 | -7.7 |

Operating Income by Segment Year-on-year


| | FYE June 2023 Q2 YTD | | FYE June 2024 Q2 YTD | | | |
|--|----------------------|----------------------|----------------------|----------------------|-------------------|-------------|
| | Amount (Mil.Yen) | Operating margin (%) | Amount (Mil.Yen) | Operating margin (%) | Changes (Mil.Yen) | Changes (%) |
| Operating income excluding goodwill amortization, etc. | | | | | | |
| Medical | 9,654 | 24.3 | 14,183 | 29.3 | +4,529 | +46.9 |
| Device | 3,389 | 59.0 | 2,607 | 43.7 | -781 | -23.1 |
| Erasing & Head Quarters | -2,142 | - | -2,307 | - | -164 | +7.7 |
| Total | 10,901 | 24.0 | 14,484 | 26.7 | +3,583 | +32.9 |
| Operating income | | | | | | |
| Medical | 8,705 | 21.9 | 13,198 | 27.3 | +4,493 | +51.6 |
| Device | 3,389 | 59.0 | 2,607 | 43.7 | -781 | -23.1 |
| Erasing & Head Quarters | -2,142 | - | -2,307 | - | -164 | +7.7 |
| Total | 9,951 | 21.9 | 13,498 | 24.8 | +3,547 | +35.6 |
| (Reference) | | | | | | |
| Device Division Segment Revenue | 7,655 | - | 6,761 | - | -893 | -11.7 |

Earnings Performance by Segment




Attribution Analysis of Operating Income – 1

(Exchange Rate Fluctuations Included)



Attribution Analysis of Operating Income – 2

(Exchange Rate Fluctuations Excluded)




Situation Per Segment Division

Per Segment by Medical Division (by Geography-1)

【Revenue (YoY)】

~ Progressed favorably due to increased overseas revenue owing to exchange rate fluctuation, the recovery and expansion of cases and strong demand, etc. ~

- Japan : Increased in Non-cardiovascular and OEM business
 - Cardiovascular field : Increased mainly PCI GW
 - Non-cardiovascular field : Increased in Gastrointestinal field and first sales of the surgery support robot "ANSUR"
 - OEM Business : Increased in Cardiovascular and Gastrointestinal field in OEM business
- Overseas : Increased in all regions due to exchange rate fluctuation, recovering and expanding cases and strong demand
 - US
 - Cardiovascular field : Increased in mainly in PCI GW/Penetration Catheter
 - Non-cardiovascular field : Increased in Peripheral vascular products (New product "CROSSLEAD", "CROSSWALK" effect)
 - OEM Business: Increased in new orders of Cardiovascular
 - Europe
 - Cardiovascular field : Increased in PCI GW/Penetration Catheter, concentrated orders for eastern Europe
 - Non-cardiovascular field : Slightly increased mainly Neurovascular products
 - China
 - Cardiovascular field : Strong sales of PCI GW, Penetration Catheter and Balloon Catheter (purchased products)
 - Non-cardiovascular field : Increased mainly in all fields such as Abdominal vascular, Peripheral vascular and Neurovascular products
 - Other
 - Cardiovascular field : Strong sales of PCI GW/Penetration Catheter mainly in Asia
 - Non-cardiovascular field : Strong sales in Abdominal vascular and Peripheral vascular products mainly in Asia



【Operating Income】


Operating income increased in proportion to revenue

Per Segment by Medical Division (by Geography-2)

| (Mil. Yen) | | FYE June 2023 Q2 YTD | FYE June 2024 Q2 YTD | YoY | |
|------------------------|------|-------------------------|-------------------------|---------------|--------------|
| | | | | Changes | Changes (%) |
| Exchange rate (Yen) | USD | 139.97 | 146.35 | +6.38 | +4.6 |
| | EURO | 141.84 | 158.20 | +16.36 | +11.5 |
| | CNY | 20.03 | 20.20 | +0.17 | +0.8 |
| Total Revenue | | 39,695 | 48,369 | +8,674 | +21.9 |
| Japan | | 6,600 | 7,247 | +647 | +9.8 |
| Overseas | | 33,094 | 41,122 | +8,027 | +24.3 |
| US | | 8,845 | 10,604 | +1,759 | +19.9 |
| Europe | | 8,643 | 11,243 | +2,599 | +30.1 |
| China | | 9,889 | 12,182 | +2,293 | +23.2 |
| Other | | 5,716 | 7,091 | +1,375 | +24.1 |
| Operating income | | 8,705 | 13,198 | +4,493 | +51.6 |

Per Segment by Medical Division (by Treatment-1)

【Revenue (YoY)】



Cardiovascular

- Japan : Increased mainly PCI GW
- Overseas : Increased due to exchange rate fluctuation, recovering and expanding the number of cases and strong demand
 - US: Increased mainly PCI GW / Penetration Catheter
 - Europe : Increased PCI GW/Penetration Catheter, concentrated orders for eastern Europe
 - China : Strong sales of PCI GW, Penetration Catheter and Balloon Catheter (purchased products)
 - Other : Strong sales of PCI GW/Penetration Catheter mainly in Asia

Non-Cardiovascular

- Japan : Increased in Gastrointestinal products
First delivery of surgery support robot "ANSUR"
- Overseas : Increased in US, China and Asia
 - US : Increased in Peripheral vascular products owing to the effect of new products 'CROSSLEAD' and 'CROSSWALK'
 - Europe : Slightly increased mainly in Neurovascular products
 - China : Increased in all fields such as Abdominal vascular, Peripheral vascular and Neurovascular products
 - Other : Strong sales in Abdominal vascular and Peripheral vascular products mainly in Asia


OEM

- Japan : Strong sales of component transaction for Cardiovascular and Gastrointestinal fields
- Overseas : Increased in US (New orders of Cardiovascular) and Asia regions, etc.

Per Segment by Medical Division (by Treatment-2)

| (Mil. Yen) | | FYE June 2023 Q2 YTD | FYE June 2024 Q2 YTD | YoY | |
|------------------------|----------|-------------------------|-------------------------|---------------|--------------|
| | | | | Changes | Changes(%) |
| Exchange rate (Yen) | USD | 139.97 | 146.35 | +6.38 | +4.6 |
| | EURO | 141.84 | 158.20 | +16.36 | +11.5 |
| | CNY | 20.03 | 20.20 | +0.17 | +0.8 |
| Total Revenue | | 39,695 | 48,369 | +8,674 | +21.9 |
| | Japan | 6,600 | 7,247 | +647 | +9.8 |
| | Overseas | 33,094 | 41,122 | +8,027 | +24.3 |
| Cardiovascular | | 30,096 | 36,300 | +6,203 | +20.6 |
| | Japan | 3,994 | 4,134 | +139 | +3.5 |
| | Overseas | 26,101 | 32,165 | +6,063 | +23.2 |
| Non-Cardiovascular | | 6,048 | 7,635 | +1,587 | +26.2 |
| | Japan | 1,843 | 2,107 | +263 | +14.3 |
| | Overseas | 4,204 | 5,528 | +1,323 | +31.5 |
| OEM | | 3,550 | 4,434 | +883 | +24.9 |
| | Japan | 761 | 1,005 | +244 | +32.1 |
| | Overseas | 2,789 | 3,428 | +639 | +22.9 |

Per Segment by Device Division-1



【Revenue (YoY)】

Increased medical components in overseas market mainly in US

Medical Component

- Japan : Increased in components sales for robotics and endoscopy
- Overseas : Increased in Cardiovascular ultrasound catheter components for US companies

Industrial Component

- Japan : Shrunk in construction related transactions
- Overseas : Decreased in leisure-related transactions

【Operating income】

Decreased due to decreasing intersegment transactions although external revenue increased

Per Segment by Device Division-2

| (Mil. Yen) | | FYE June 2023 Q2 YTD | FYE June 2024 Q2 YTD | YoY | |
|-----------------------------|----------|-------------------------|-------------------------|--------------|--------------|
| | | | | Changes | Changes (%) |
| Exchange rate (Yen) | USD | 139.97 | 146.35 | +6.38 | +4.6 |
| Total Revenue | | 5,740 | 5,972 | +231 | +4.0 |
| | Japan | 1,427 | 1,430 | +3 | +0.2 |
| | Overseas | 4,313 | 4,541 | +227 | +5.3 |
| Medical Components | | 3,450 | 3,857 | +406 | +11.8 |
| | Japan | 488 | 588 | +100 | +20.6 |
| | Overseas | 2,962 | 3,268 | +306 | +10.3 |
| Industrial Components | | 2,290 | 2,114 | -175 | -7.7 |
| | Japan | 938 | 841 | -97 | -10.4 |
| | Overseas | 1,351 | 1,273 | -78 | -5.8 |
| Operating income | | 3,389 | 2,607 | -781 | -23.1 |
| (Reference) Segment Revenue | | 7,655 | 6,761 | -893 | -11.7 |


Reference: P/L

| | FYE June 2023 Q2 YTD | | FYE June 2024 Q2 YTD | | | |
|--|----------------------|--------------|----------------------|--------------|-----------------------|---|
| | Amount (Mil. Yen) | Ratio (%) | Amount (Mil. Yen) | Ratio (%) | Changes (Mil. Yen) | Main comparison factors |
| Revenue | 45,435 | 100.0 | 54,341 | 100.0 | +8,906 | <ul style="list-style-type: none"> •Strong demand due to recovering and expanding cases •Exchange rate fluctuation (Yen depreciation) |
| Cost of sales | 15,395 | 33.9 | 19,150 | 35.2 | +3,754 | |
| Gross profit | 30,040 | 66.1 | 35,191 | 64.8 | +5,151 | |
| SGA | 20,088 | 44.2 | 21,693 | 39.9 | +1,604 | <ul style="list-style-type: none"> •Increased in expenses related to sales and R&D |
| Operating income excl. goodwill amortization | 10,901 | 24.0 | 14,484 | 26.7 | +3,583 | |
| Operating income | 9,951 | 21.9 | 13,498 | 24.8 | +3,547 | |
| Non-operating income | 110 | 0.2 | 301 | 0.6 | +190 | |
| Non-operating expense | 440 | 1.0 | 328 | 0.6 | -112 | |
| Ordinary income | 9,621 | 21.2 | 13,471 | 24.8 | +3,849 | |
| Extraordinary income | 305 | 0.7 | – | – | -305 | <ul style="list-style-type: none"> •Occurrence insurance proceeds on disaster at Cebu factory in the previous quarter |
| Extraordinary loss | 72 | 0.2 | 99 | 0.2 | +27 | |
| Net income attributable to parent company shareholders | 7,473 | 16.4 | 9,820 | 18.1 | +2,346 | |
| Quarterly Comprehensive income | 7,115 | 15.7 | 9,700 | 17.9 | +2,584 | |

Reference: B/S

| | | FYE June 2023 Results | | FYE June 2024 Q2 YTD | | | |
|--------------------------------|---------------------|-----------------------|--------------|----------------------|--------------|-----------------------|---|
| | | Amount (Mil. Yen) | Ratio (%) | Amount (Mil. Yen) | Ratio (%) | Changes (Mil. Yen) | Main comparison factors |
| Assets | Current assets | 90,261 | 52.3 | 87,384 | 51.7 | -2,877 | Notes and accounts receivable +2,943 Inventories - 1,362 Securities - 2,000 Cash and deposit - 2,376 |
| | Fixed assets | 82,383 | 47.7 | 81,707 | 48.3 | -675 | Goodwill - 653 |
| Total assets | | 172,644 | 100.0 | 169,091 | 100.0 | -3,553 | |
| Liabilities | Current liabilities | 26,316 | 15.2 | 21,963 | 13.0 | -4,352 | Notes and accounts payable - 637 Short-term borrowings - 2,761 Others - 1,509 |
| | Fixed liabilities | 12,028 | 7.0 | 8,344 | 4.9 | -3,683 | Long-term borrowings -3,804 |
| Total liabilities | | 38,344 | 22.2 | 30,307 | 17.9 | -8,036 | |
| Total net assets | | 134,300 | 77.8 | 138,783 | 82.1 | +4,483 | Retained earnings +5,887 Non-controlling interests - 1,254 |
| Total liabilities & net assets | | 172,644 | 100.0 | 169,091 | 100.0 | -3,553 | |

Reference: C/F



Caution Regarding Information Presented

All forward looking statements contained herein, including revenue forecasts, outlooks, and strategic plans, are based on the best currently available data; however, risk and uncertainty are involved in these statements.

Please note that actual results may differ greatly from plans presented here.

[IR contact]

Asahi Intecc Co., Ltd.
corporate strategic office

TEL 0561-48-5551

URL <http://www.asahi-intecc.co.jp/en/>